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journal homepage: www.elsevier.com/locate/ihjAtrial ﬁbrillation (AF) is the commonest cardiac arrhythmia
and represents a global healthcare problem.1 The main priority
in AF management is stroke prevention,2 and following this,
having a patient-centered and symptom-directed approach to
consider rate or rhythm control. Of course, given the
association of AF with various comorbidities, attention to
correction and/or treatment of risk factors such as hyperten-
sion, diabetes, and heart failure is part of the holistic approach
to AF management.
While the risk of stroke in AF is increased ﬁvefold, this risk
is not homogeneous and depends on the presence or absence
of various stroke risk factors. The latter has been incorporated
into stroke risk stratiﬁcation scores, such as the CHADS2 and
CHA2DS2-VASc scores.
2 With regard to stroke prevention, all
the major guidelines (European,3 American,4 and National
Institute for Health and Care Excellence (NICE)5) now recom-
mend use of the CHA2DS2-VASc score
6 for stroke risk
stratiﬁcation.
A simpliﬁed approach to stroke prevention is shown in
Fig. 1.7 The initial focus on identiﬁcation of 'truly low-risk'
patients with AF [STEP 1], that is, those patients who are with a
CHA2DS2-VASc score = 0 (male) or 1 (female) and those who do
not need any antithrombotic therapy. Subsequent to this [STEP
2], patients with AF and ≥1 stroke risk factors can be offered
effective stroke prevention, which is essentially oral antic-
oagulation. Oral anticoagulation is given either as a Non-
Vitamin K Antagonist Oral Anticoagulant (NOAC) or as a
Vitamin K Antagonist (VKA, e.g. warfarin) with good quality
anticoagulation control as reﬂected by a time in therapeutic
range (TTR) >70%.
Use of the NOACs is supported by a strong evidence base
from large well-conducted clinical trials. However, translating
the evidence to everyday clinical practice is another matter.8
Also, some patient groups were not studied in the NOAC trials,
and additional research is still required.9 For now, how best to
manage such patients requires some expert consensus-based
advice.
Given the increasing use of NOACs, the Indian consensus
guidance paper on stroke prevention in AF by Dalal et al. in§ This editorial is pertaining to the article: The Indian Consensus Gu
Practical Use of Non-Vitamin K Oral Anticoagulants.this issue of the Indian Heart Journal is very timely,
particularly with its emphasis on practical use of NOACs.
The latter drugs are relatively new, and thus, many
clinicians have questions on how and when to use these
drugs. Important practical approaches are highlighted and
schemes to help everyday management are suggested.
Indeed, the approaches are complementary to similar
practical guides, such as the European Heart Rhythm
practical guide on NOACs, which has recently been
updated.10
Translating to clinical practice can sometimes raise
questions on patient populations with less limited data. For
example, some discussion is whether a single risk factor (e.g.
CHA2DS2-VASc score = 1 in males, 2 in females) merits oral
anticoagulation.11,12 Unsurprisingly, differences in stroke rates
would be evident between stable community-based 'uncom-
plicated' outpatients and patients with a ﬁrst-time AF
diagnosis which is often discovered during an in-hospital
stay, whether AF was the primary diagnosis or with AF
secondary to other acute disease.
Of note, recent data from Asia and Europe13,14 show
ischemic stroke rates of 1.5–3%/year with a single stroke risk
factor (i.e. CHA2DS2-VASc 1 in males, 2 in females). The net
clinical beneﬁt is also positive for OAC vs untreated or OAC vs
aspirin; in contrast, the NCB is neutral/negative for aspirin vs
untreated.15
Thus, clinicians need to ask themselves whether it is worth
taking the risk of exposing such AF patients to fatal and
disabling strokes. Indeed, AF patients are also not 'static' in
relation to their risk proﬁle, being elderly and having multiple
comorbidities.
Some healthcare systems also manage warfarin very
well, and hence, a question often asked is how to identify
those patients likely to do well on warfarin (with a high TTR,
and hence, low rates of thromboembolism and bleed-
ing16,17), rather than a blanket 'NOAC for everyone' policy
or a 'trial of warfarin' approach which leaves patients with
suboptimal anticoagulation control for the initial few
months prior to a decision being taken about whether aidance on Stroke Prevention in Atrial Fibrillation: An Emphasis on
Fig. 1
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19 has
recently been introduced to help physicians make informed
decisions on those patients likely to do well on warfarin
(SAMe-TT2R2 score 0–2) or those where on probability are
likely to have a poor TTR (SAMe-TT2R2 score >2). The latter
group would beneﬁt from more intense counseling, educa-
tion, and follow-up, or preferentially, a NOAC.18,20,21
In conclusion, the NOACs are here to stay – but they are
no longer new nor novel.22–24 These drugs work well, if used
appropriately and correctly in the right patients.25 The
Indian consensus document is a timely and valued addition
to providing practical guidance on how best to use such
drugs in a safe and appropriate manner. After all, prescrib-
ing label or guideline adherent treatment is associated with
far improved outcomes in AF patients. Things can only get
better.
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